Alpha 2.0
Login Register
» Articles » PMID: 37069895

Heterologous Inactivated Virus/mRNA Vaccination Response to BF.7, BQ.1.1, and XBB.1

Overview
Journal Lancet Reg Health West Pac
Date 2023 Apr 18
PMID 37069895
Authors
Fanglei Zuo
Rui Sun
Hassan Abolhassani
Likun Du
Yating Wang
Stelios Vlachiotis
Federico Bertoglio
Maren Schubert
Nima Rezaei
Zahra Chavoshzadeh
Concetta Guerra
Andrea Cavalli
Juni Andrell
Makiko Kumagai-Braesch
Yintong Xue
Yunlong Cao
Michael Hust
Davide F Robbiani
Xiaoliang Sunney Xie
Lennart Hammarstrom
Harold Marcotte
Qiang Pan-Hammarstrom
Affiliations
Soon will be listed here.
Citing Articles

Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study.

Peng D, Yang L, Jin C, Feng J, Cao M, Liu Y Heliyon. 2024; 10(1):e23344.

PMID: 38169898 PMC: 10758784. DOI: 10.1016/j.heliyon.2023.e23344.

Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.

Chen K, Zhang L, Fang Z, Li J, Li C, Song W Front Immunol. 2023; 14:1294288.

PMID: 38090587 PMC: 10711607. DOI: 10.3389/fimmu.2023.1294288.

Design, structure and plasma binding of ancestral β-CoV scaffold antigens.

Hueting D, Schriever K, Sun R, Vlachiotis S, Zuo F, Du L Nat Commun. 2023; 14(1):6527.

PMID: 37845250 PMC: 10579346. DOI: 10.1038/s41467-023-42200-x.

Breakthrough SARS-CoV-2 Omicron Variant in Individuals Primed with Heterologous Vaccines Enhances Inhibition Performance of Neutralizing Antibody to BA.2 Parental Lineage.

Szekely J, Swangphon P, Nanakorn N, Chaimuti P, Nualnoi T, Wongwitwichot P Vaccines (Basel). 2023; 11(7).

PMID: 37515045 PMC: 10383937. DOI: 10.3390/vaccines11071230.

References
1.
Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J . Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529. PMC: 9931576. DOI: 10.1038/s41586-022-05644-7. View
2.
Qu P, Evans J, Faraone J, Zheng Y, Carlin C, Anghelina M . Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2022; 31(1):9-17.e3. PMC: 9678813. DOI: 10.1016/j.chom.2022.11.012. View
3.
Marcotte H, Hammarstrom L, Pan-Hammarstrom Q . Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster. Signal Transduct Target Ther. 2022; 7(1):294. PMC: 9395412. DOI: 10.1038/s41392-022-01146-0. View
4.
Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L . Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022; 13(1):2670. PMC: 9106736. DOI: 10.1038/s41467-022-30340-5. View
5.
Kurhade C, Zou J, Xia H, Liu M, Chang H, Ren P . Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022; 29(2):344-347. DOI: 10.1038/s41591-022-02162-x. View